AstraZeneca PLC announced plans to invest $2 billion in expanding its operations in Maryland, as part of a broader $50 billion U.S. investment initiative disclosed earlier this year.

The British pharmaceutical giant stated that the investment will expand its flagship biologics manufacturing site in Frederick and establish a new facility in Gaithersburg, dedicated to developing and supplying molecules for clinical trials.

AstraZeneca said on Friday that the expansion will nearly double the capacity of the Frederick site, boosting supply for existing medicines and enabling the production of rare disease treatments for the first time. The project is expected to create 200 new jobs and 900 construction roles, with operations slated to begin by 2029.

The new clinical production facility in Gaithersburg will further extend the company's local footprint. AstraZeneca anticipates the site to become operational by 2029, generating 100 new jobs, retaining 400 positions, and supporting 1,000 construction-related roles.

This marks AstraZeneca’s fourth major U.S. manufacturing investment announcement this year. In July, the company pledged $50 billion toward drug production and R&D in the U.S.